Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:2579-2588
Published online before print May 30, 2006, doi: 10.1161/CIRCULATIONAHA.106.625467
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
113/22/2579    most recent
CIRCULATIONAHA.106.625467v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kong, Y.
Right arrow Articles by Hill, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kong, Y.
Right arrow Articles by Hill, J. A.
Related Collections
Right arrow Congestive
Right arrow Animal models of human disease
Right arrow Heart failure - basic studies
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression

(Circulation. 2006;113:2579-2588.)
© 2006 American Heart Association, Inc.


Heart Failure

Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy

Yongli Kong, MD, PhD; Paul Tannous, BS; Guangrong Lu, MD; Kambeez Berenji, MD; Beverly A. Rothermel, PhD; Eric N. Olson, PhD; Joseph A. Hill, MD, PhD

From the Donald W. Reynolds Cardiovascular Clinical Research Center (E.N.O., J.A.H.) and the Departments of Internal Medicine (Y.K., P.T., G.L., K.B., B.A.R., J.A.H.) and Molecular Biology (E.N.O., J.A.H.), University of Texas Southwestern Medical Center, Dallas.

Correspondence to Joseph A. Hill, MD, PhD, Division of Cardiology, UT Southwestern Medical Center, NB11.200, 6000 Harry Hines Blvd, Dallas, TX 75390–8573. E-mail joseph.hill{at}UTSouthwestern.edu

Received November 21, 2005; de novo received March 7, 2006; revision received April 1, 2006; accepted April 7, 2006.

Background— Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. In cell culture models of cardiac hypertrophy, pharmacological suppression of histone deacetylases (HDACs) can either blunt or amplify cell growth. Thus, HDAC inhibitors hold promise as potential therapeutic agents in hypertrophic heart disease.

Methods and Results— In the present investigation, we studied 2 broad-spectrum HDAC inhibitors in a physiologically relevant banding model of hypertrophy, observing dose-responsive suppression of ventricular growth that was well tolerated in terms of both clinical outcome and cardiac performance measures. In both short-term (3-week) and long-term (9-week) trials, cardiomyocyte growth was blocked by HDAC inhibition, with no evidence of cell death or apoptosis. Fibrotic change was diminished in hearts treated with HDAC inhibitors, and collagen synthesis in isolated cardiac fibroblasts was blocked. Preservation of systolic function in the setting of blunted hypertrophic growth was documented by echocardiography and by invasive pressure measurements. The hypertrophy-associated switch of adult and fetal isoforms of myosin heavy chain expression was attenuated, which likely contributed to the observed preservation of systolic function in HDAC inhibitor–treated hearts.

Conclusions— Together, these data suggest that HDAC inhibition is a viable therapeutic strategy that holds promise in the treatment of load-induced heart disease.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Circ. Res.Home page
E. W. Bush and T. A. McKinsey
Protein Acetylation in the Cardiorenal Axis: The Promise of Histone Deacetylase Inhibitors
Circ. Res., February 5, 2010; 106(2): 272 - 284.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. van Rooij, J. Fielitz, L. B. Sutherland, V. L. Thijssen, H. J. Crijns, M. J. Dimaio, J. Shelton, L. J. De Windt, J. A. Hill, and E. N. Olson
Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor
Circ. Res., January 8, 2010; 106(1): 155 - 165.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. Chandrasekaran, R. E. Peterson, S. K. Mani, B. Addy, A. L. Buchholz, L. Xu, T. Thiyagarajan, H. Kasiganesan, C. B. Kern, and D. R. Menick
Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes
FASEB J, November 1, 2009; 23(11): 3851 - 3864.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. Noh, E. Y. Oh, J. Y. Seo, M. R. Yu, Y. O. Kim, H. Ha, and H. B. Lee
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-{beta}1-induced renal injury
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F729 - F739.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. E. Pandorf, F. Haddad, C. Wright, P. W. Bodell, and K. M. Baldwin
Differential epigenetic modifications of histones at the myosin heavy chain genes in fast and slow skeletal muscle fibers and in response to muscle unloading
Am J Physiol Cell Physiol, July 1, 2009; 297(1): C6 - C16.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. Sharma, M. M. Mehan, S. Sinha, J. W. Cowden, and R. R. Mohan
Trichostatin A Inhibits Corneal Haze In Vitro and In Vivo
Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2695 - 2701.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. J. Glenn, F. Wang, S. Chen, M. Nishimoto, and D. G. Gardner
Endothelin-Stimulated Human B-Type Natriuretic Peptide Gene Expression Is Mediated by Yin Yang 1 in Association With Histone Deacetylase 2
Hypertension, March 1, 2009; 53(3): 549 - 555.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. Gallo, M. V.G. Latronico, P. Gallo, S. Grimaldi, F. Borgia, M. Todaro, P. Jones, P. Gallinari, R. De Francesco, G. Ciliberto, et al.
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure
Cardiovasc Res, December 1, 2008; 80(3): 416 - 424.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. J. Kee, G. H. Eom, H. Joung, S. Shin, J.-R. Kim, Y. K. Cho, N. Choe, B.-W. Sim, D. Jo, M. H. Jeong, et al.
Activation of Histone Deacetylase 2 by Inducible Heat Shock Protein 70 in Cardiac Hypertrophy
Circ. Res., November 21, 2008; 103(11): 1259 - 1269.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. Trivedi, M. M. Lu, Q. Wang, and J. A. Epstein
Transgenic Overexpression of Hdac3 in the Heart Produces Increased Postnatal Cardiac Myocyte Proliferation but Does Not Induce Hypertrophy
J. Biol. Chem., September 26, 2008; 283(39): 26484 - 26489.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Q. Wei, L. A. Shehadeh, J. M. Mitrani, M. Pessanha, T. I. Slepak, K. A. Webster, and N. H. Bishopric
Quantitative Control of Adaptive Cardiac Hypertrophy by Acetyltransferase p300
Circulation, August 26, 2008; 118(9): 934 - 946.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Su, L. Altucci, and Q. You
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. P. Gupta, S. A. Samant, S. H. Smith, and S. G. Shroff
HDAC4 and PCAF Bind to Cardiac Sarcomeres and Play a Role in Regulating Myofilament Contractile Activity
J. Biol. Chem., April 11, 2008; 283(15): 10135 - 10146.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. G. Edwards
Cardiac MHC gene expression: more complexity and a step forward
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H14 - H15.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. C. Zhao, G. Cheng, L. X. Zhang, Y. T. Tseng, and J. F. Padbury
Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury
Cardiovasc Res, December 1, 2007; 76(3): 473 - 481.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
R. L. Montgomery, C. A. Davis, M. J. Potthoff, M. Haberland, J. Fielitz, X. Qi, J. A. Hill, J. A. Richardson, and E. N. Olson
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Genes & Dev., July 15, 2007; 21(14): 1790 - 1802.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. A. McKinsey
Derepression of pathological cardiac genes by members of the CaM kinase superfamily
Cardiovasc Res, March 1, 2007; 73(4): 667 - 677.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
A. Diwan and G. W. Dorn II
Decompensation of Cardiac Hypertrophy: Cellular Mechanisms and Novel Therapeutic Targets
Physiology, February 1, 2007; 22(1): 56 - 64.
[Abstract] [Full Text] [PDF]